

Factsheet H1/2013



COMPANY PROFILE

Fresenius is a health care group providing products and services for dialysis, hospitals and the medical care of patients at home. In addition, Fresenius focuses on hospital operation, as well as on engineering and services for hospitals and other health care facilities. Approximately 173,000 employees have dedicated themselves to the service of health in about 100 countries worldwide.

FRESENIUS GROUP IN FIGURES

€ in millions	H1/2013	Change	2012	Change
Sales and Earnings				
Sales	9,987	8%	19,290	18%
EBIT ¹	1,448	1%	3,075	20%
Net income (before special items) ²	482	11%	938	22%
Earnings per ord. share in € (before special items) ²	2.70	5%	5.42	15%
Balance sheet and cash flow				
Total assets	30,973	1%	30,664	17%
Non-current assets	22,716	1%	22,551	18%
Equity ³	12,955	2%	12,758	21%
Equity ratio ³	42%	--	42%	--
Net debt/EBITDA ⁴	2.63	--	2.56	--
Investments ⁵	575	-83%	4,179	74%
Operating cash flow	947	-17%	2,438	44%
Operating cash flow in % of sales	9.5%	--	12.6%	--
Profitability				
EBIT margin ¹	14.5%	--	15.9%	--
Return on equity after taxes (ROE) ²	12.6%	--	12.3%	--
Return on operating assets (ROOA) ¹	10.4%	--	11.0%	--
Return on invested capital (ROIC) ¹	8.7%	--	9.0%	--
Employees (Jun 30/Dec 31)	173,325	2%	169,324	13%

¹ 2013 excluding one-time integration costs of Fenwal
2012 before one-time items

² Net income attributable to shareholders of Fresenius SE & Co. KGaA;
2013 excluding one-time integration costs of Fenwal,

2012 before one-time items


³ Including noncontrolling interest

⁴ Pro forma before special items

⁵ Investments in property, plant and equipment and intangible assets, acquisitions; 2012 including an investment of cash in the amount of €952 million by Fresenius SE & Co. KGaA

GROUP STRUCTURE

The operating business comprises the four business segments Fresenius Medical Care, Fresenius Kabi, Fresenius Helios and Fresenius Vamed, all of which are legally independent entities managed by the operating parent company Fresenius SE & Co. KGaA.




BUSINESS SEGMENTS


€ in millions	H1/2013	Change	2012	Change
FRESENIUS MEDICAL CARE Sales	5,388	5%	10,741	19%
EBIT	790	-6%	1,813	22%
FRESENIUS KABI Sales	2,519	13%	4,539	15%
EBIT	469	4%	934	16%
FRESENIUS HELIOS Sales	1,695	11%	3,200	20%
EBIT	179	19%	322	19%
FRESENIUS VAMED Sales	421	21%	846	15%
EBIT	15	7%	51	16%

- ▶ **Fresenius Medical Care** is the world's leading provider of services and products for patients with chronic kidney failure. As of June 30, 2013, Fresenius Medical Care was treating 264,290 patients in 3,212 dialysis clinics.
- ▶ **Fresenius Kabi** offers infusion therapies, intravenously administered generic drugs and clinical nutrition for seriously and chronically ill patients in the hospital and outpatient environments. The company is also a leading supplier of medical devices and transfusion technology products in Germany.
- ▶ **Fresenius Helios** is one of the largest private hospital operators in Germany. HELIOS owns 74 hospitals, including 6 maximum care hospitals in Berlin-Buch, Duisburg, Erfurt, Krefeld, Schwerin and Wuppertal. HELIOS treats more than 2.9 million patients per year, thereof more than 780,000 inpatients, and operates more than 23,000 beds.
- ▶ **Fresenius Vamed** offers engineering and services for hospitals and other health care facilities.

SALES BY REGION



SALES BY BUSINESS SEGMENT



FRESENIUS SHARE/ADR


	Share
Securities code no.	578 560
ISIN	DE0005785604
Ticker symbol	FRE
ADR CUSIP	35804M105
ADR Ticker symbol	FSNUY
Number of shares (June 30, 2013)	178,432,957
Market capitalization (June 30, 2013)	€16.9 billion

FRESENIUS GROUP'S SENIOR NOTES

Issuer	ISIN	Volume in million	Coupon	Maturity
Fresenius Finance B. V.	XS0759200321	€500	4.25 %	2019
Fresenius Finance B. V.	XS0873432511	€500	2.875 %	2020
Fresenius US Finance II, Inc.	USU31436AD72	US\$500	9.00 %	2015
Fresenius US Finance II, Inc.	XS0390398344	€275	8.75 %	2015

Bonds of Fresenius Medical Care can be found under [www.fmc-ag.com/Credit Relations](http://www.fmc-ag.com/Credit_Relations).

RELATIVE SHARE PRICE PERFORMANCE FRESENIUS SHARE VS. DAX




SHARE PERFORMANCE¹

1 month	+3.5 %
1 quarter	-1.6 %
1 st half	+8.7 %
1 year	+15.3 %
5 years	+72.3 %
10 years	+511.8 %

¹ Effective date/closing price: June 30, 2013

DEVELOPMENT ORDINARY SHARE DIVIDENDS IN €



This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.

Fresenius SE & Co. KGaA
Registered Office: Bad Homburg, Germany
Commercial Register: Amtsgericht Bad Homburg, HRB 11852
Chairman of the Supervisory Board: Dr. Gerd Krick

General Partner: Fresenius Management SE
Registered Office: Bad Homburg, Germany
Commercial Register: Amtsgericht Bad Homburg, HRB 11673
Management Board: Dr. Ulf M. Schneider (Chairman), Mats Henriksson, Dr. Francesco De Meco, Dr. Jürgen Götz, Rice Powell, Stephan Sturm, Dr. Ernst Wastler
Chairman of the Supervisory Board: Dr. Gerd Krick

GROUP OUTLOOK 2013

	Targets 2013
Sales growth (in constant currency)	7% – 10%
Net income ¹ , growth (in constant currency)	11% – 14%
Capital expenditure	~5% of group sales

¹ Net income attributable to shareholders of Fresenius SE & Co. KGaA; 2013 adjusted for one-time integration costs of Fenwal, Inc. (–€50 million pre tax); 2012 adjusted for an investment gain and other one-time costs at Fresenius Medical Care as well as for one-time costs related to the takeover offer to the shareholders of RHÖN-KLINIKUM AG.

For the outlook of the business segments please see the Investor News of July 30, 2013.

FINANCIAL CALENDAR

	Dates
Report on 1 st –3 rd quarter 2013	November 5, 2013
Report on Fiscal Year 2013	February 25, 2014
Report on 1 st quarter 2014	May 6, 2014
Annual General Meeting, Frankfurt/Main	May 16, 2014
Report on 1 st half 2014	August 5, 2014
Report on 1 st –3 rd quarter 2014	November 4, 2014

CONTACT

Fresenius SE & Co. KGaA

Else-Kröner-Straße 1, 61352 Bad Homburg v. d. H.

e-mail: ir-fre@fresenius.com

Internet: www.fresenius.com

Birgit Grund
Senior Vice President
Investor Relations

Telephone: ++49 61 72 6 08-24 85

Telefax: ++49 61 72 6 08-24 88

Leslie Iltgen
Vice President
Investor Relations

Telephone: ++49 61 72 6 08-44 78

Telefax: ++49 61 72 6 08-24 88